We are live on
!
Find out more
ESPR
Esperion Therapeutics
ESPR
ESPR
Delisted
ESPR was delisted on the 10th of July, 2026.
165 hedge funds and large institutions have $930M invested in Esperion Therapeutics in 2020 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 58 increasing their positions, 48 reducing their positions, and 36 closing their positions.
New
Increased
Maintained
Reduced
Closed
21% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 48
6.49% more ownership
Funds ownership: 101.9% → 108.38% (+6.5%)
4% less funds holding
Funds holding: 172 → 165 (-7)
11% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 36
31% less call options, than puts
Call options by funds: $9.76M | Put options by funds: $14.2M
43% less capital invested
Capital invested by funds: $1.62B → $930M (-$691M)
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
Holders
165
Holders Change
-7
Holders Change %
-4.07%
% of All Funds
3.64%
Holding in Top 10
3
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-50%
% of All Funds
0.07%
New
32
Increased
58
Reduced
48
Closed
36
Calls
$9.76M
Puts
$14.2M
Net Calls
-$4.41M
Net Calls Change
-$15M
Top Buyers
Top Sellers
| 1 |
Nomura Holdings
Tokyo,
Japan
|
-$17.2M |
| 2 |
Man Group
London,
United Kingdom
|
-$14.6M |
| 3 |
Millennium Management
New York
|
-$9.13M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$9.08M |
| 5 |
Goldman Sachs
New York
|
-$8.91M |
